Sarepta Therapeutics Stock
Price
Target price
€143.50
€143.50
-1.710%
-
-1.710%
€187.50
02.07.24 / Tradegate
WKN: A1J1BH / Symbol: AVII / Name: Sarepta / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Sarepta Therapeutics Stock
A loss of -1.710% shows a downward development for Sarepta Therapeutics.
Sarepta Therapeutics is currently one of the favorites of our community with 8 Buy predictions and no Sell predictions.
With a target price of 187 € there is a positive potential of 30.31% for Sarepta Therapeutics compared to the current price of 143.5 €.
So far the community has only identified positive things for Sarepta Therapeutics stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Sarepta Therapeutics in the next few years
Pros
?
S********** s********
?
M***** P*******
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sarepta Therapeutics vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Sarepta Therapeutics | -1.710% | -2.679% | 19.933% | 36.667% | 62.184% | 117.490% | 7.090% |
Exact Sciences | -0.340% | 4.093% | -4.105% | -53.295% | -41.369% | -61.160% | -60.808% |
Incyte Corp. | -3.170% | -6.692% | 3.154% | -3.682% | -3.172% | -22.005% | -26.854% |
Regeneron Pharmaceuticals Inc. | -2.340% | -2.761% | 7.617% | 47.496% | 21.881% | 97.561% | 244.193% |
Comments
News
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
When one player stumbles in a high-stakes competition, it's often to the glee of the other contenders. In mid-June, Pfizer's (NYSE: PFE) gene-therapy candidate to treat Duchenne muscular dystrophy
Sarepta Therapeutics Stock Soars on FDA Approval
Sarepta Therapeutics (NASDAQ: SRPT) is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
Sarepta Therapeutics (NASDAQ: SRPT)Q1 2024 Earnings CallMay 01, 2024, 4:30 p.m. ET
Operator
Source Fool.com